drugset / Trial / NCT01843868
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
NaSingle-groupOpen-labelSupportive care
Summary
The incidence and severity of chemotherapy-induced nausea and vomiting (CINV) in patients receiving R-CHOP chemotherapy for in non-Hodgkin's lymphoma is not well documented. The contribution of prednisolone to CINV control in the R-CHOP regimen is also unclear. This study aims to evaluate the overall effectiveness of antiemetic control using a standardised 5HT3 (5-Hydroxytryptamine 3) antagonist-containing regimen (e.g. ondansetron) in a heterogeneous group of patients receiving R-CHOP chemotherapy (Rituximab Doxorubicin Vincristine Cyclophosphamide Prednisolone).
Timeline
- Start
- 2012-01
- Primary completion
- 2015-06
- Completion
- 2015-06
Outcome
Outcome not reported
Stopped (Enrollment): “Study halted prematurely, prior to enrollment of first participant due to protracted logistical and subsequent funding matters.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aprepitant | Other / unclassified | — | — |
| Subject | Granisetron | Other / unclassified | — | — |
| Subject | Lorazepam | Small molecule | — | — |
| Subject | Metoclopramide | Small molecule | — | — |
| Subject | Ondansetron | Other / unclassified | — | — |
| Subject | Prochlorperazine | Small molecule | — | — |
| Subject | Tropisetron | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Palonosetron | Other / unclassified | — | — |
| Background | Prednisolone | Other / unclassified | — | — |
| Background | Rituximab | Monoclonal antibody | — | — |
| Background | Vincristine | Small molecule | — | — |